Consumer Staples · Miscellaneous Food Preparations & Kindred Products

MED MEDIFAST INC SEC Filings & Insider Trading Activity 2026

company
CIK 910329138 filings
Russell 2000

MED at a glance

MEDIFAST INC (MED, SEC CIK 910329) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 26, 2026, an 8-K current report on October 26, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), MEDIFAST INC (MED) reported revenue of $385.8 million (down 36.0% from FY2024) and a net loss of $18.7 million. Diluted EPS was -$1.70.
  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding MEDIFAST INC (MED) shares worth $39.9 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Kiai Parsa on November 19, 2026 of 2,450 shares at $12.05 per share.
  • In the last 90 days, MED insiders reported 11 open-market purchases ($1.8M) and 2 open-market sales ($226K) on Form 4, a net purchase of $1.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$385.8M
−36.0% vs prior year
Insiders · 90 days
11 buys · 2 sells
Net +$1.6M
13F holders
20 funds
$39.9M · −2 vs prior quarter
Latest 8-K
Oct 26, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to 2025 Form 10-K risk factors disclosed
  • Carried-forward risks include regulatory, operational, competitive, market, and financial exposures disclosed in the 2025 Form 10-K

Management Discussion & Analysis

  • Revenue $72.0M, down 19.4% YoY from $89.4M, driven by active earning coaches declining to 10,200 from 19,500
  • Gross margin 69.5% vs 69.5% YoY; operating margin (26.9%) vs (4.6%), with net loss $17.5M vs $2.3M
  • Average revenue per active earning coach $7,064, up 54.1% from $4,585, the strongest reported performance metric
  • Cash, cash equivalents and investments $172.5M vs $167.3M at December 31, 2025; operating cash flow $5.3M vs $12.1M
  • Active earning coaches expected to decline through year-end 2026; GLP-1 adoption, inflation and tariffs remain headwinds

AI summary of the MED 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 26, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 FY2026 earnings release issued October 26, 2026
  • Reporting period ended September 30, 2026

Item EX-99.1: Item EX-99.1

  • Q3 revenue $72.0M, down 19.4% YoY, as active earning coaches fell 47.7% to 10,200
  • Coach productivity improved 54.1% to $7,064, but management expects coach declines through year-end 2026
Filed Aug 3, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $76.4M, down 27.6% year over year, reflecting continued demand pressure and rapid GLP-1 adoption
  • Active earning coaches fell 48.7% to 11,700, while revenue per coach rose 41.0% to $6,529

Item 2.02: Results of Operations and Financial Condition

  • Q2 FY2026 earnings released August 3, 2026, covering the quarter ended June 30, 2026
  • Detailed financial results and management commentary contained in Exhibit 99.1
Filed Jul 17, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • OPTAVIA rebranded as Trilivy, repositioning Medifast’s wholly owned lifestyle brand around comprehensive metabolic health
  • Strategic shift broadens brand positioning beyond traditional weight management toward an integrated metabolic-health offering

AI summaries of MED 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MED

Don't miss the next MED filing

  • Alerts as it files. A push when MED files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MED, by share count.
  • Ask anything. An AI agent that reads every MED filing and answers with sources.

MED alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Kiai ParsaBuyNov 19, 2026$12.05
Kiai ParsaBuyNov 19, 2026$12.05
Kiai ParsaBuyNov 18, 2026$12.16
Kiai ParsaBuyNov 18, 2026$12.16
Kiai ParsaBuyNov 4, 2026$13.03
Kiai ParsaBuyOct 28, 2026$12.24
Kiai ParsaBuyOct 28, 2026$12.24
Chard Daniel RSellSep 29, 2026$11.73

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$602.5M$385.8M
Gross Profit-$444.6M$275.2M
Operating Income-$2.9M-$14.2M
Net Income-$2.1M-$18.7M
Gross Margin-73.8%71.3%
Op. Margin-0.5%-3.7%
Net Margin-0.3%-4.8%
Balance Sheet
Total Assets$309.9M$284.2M$248.0M
Equity$201.5M$210.1M$198.9M
ROE-1.0%-9.4%
Per Share
EPS-$0.19$-1.70
Cash Flow
Operating CF-$24.5M$6.9M
CapEx-$7.5M$5.6M

Source: XBRL data in MEDIFAST INC (MED)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MED share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MED shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$39.9M
Q2 202622$39.8M
Q1 202621$45.3M
Q4 202522$52.1M
Q3 202522$78.7M
Q2 202525$77.9M
Q1 202521$56.9M
Q4 202419$63.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 172 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MED filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 6, 2026--
4Oct 30, 2026--
10-QOct 26, 2026Analysis
8-KOct 26, 2026Analysis-
4Sep 30, 2026--
4Aug 28, 2026--
4Aug 26, 2026--
4Aug 21, 2026--
SC 13GAug 14, 2026-
10-QAug 3, 2026Analysis
8-KAug 3, 2026Analysis-
8-KJul 17, 2026Analysis-
8-KJun 1, 2026Analysis
4May 28, 2026-
4May 28, 2026-
4May 28, 2026-
4May 28, 2026-
4May 28, 2026-
4May 28, 2026-
8-KMay 26, 2026Analysis
SC 13GMay 15, 2026-
4May 12, 2026-
8-KMay 4, 2026Analysis-
10-QMay 4, 2026Analysis

Related Consumer Staples companies

All Consumer Staples →

MED SEC filings: frequently asked questions

Are MED insiders buying or selling?

In the last 90 days, MEDIFAST INC (MED) officers, directors and 10% owners reported 11 open-market purchases worth $1.8 million by 1 insider and 2 open-market sales worth $226,289 by 1 insider on Form 4, a net purchase of $1.6 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MED stock?

As of September 30, 2026, the largest MEDIFAST INC (MED) holders among the 13F filers tracked by SignalX were Renaissance Technologies LLC ($9.9 million), BlackRock ($5.9 million), Two Sigma Investments ($5.7 million), Vanguard Capital Management LLC ($5.1 million), Dimensional Fund Advisors ($4.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MED's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), MEDIFAST INC (MED) reported revenue of $385.8 million (down 36.0% from FY2024) and a net loss of $18.7 million. Diluted EPS was -$1.70. The figures come from the XBRL data in the 10-K.

What did MED report in its latest 8-K?

MEDIFAST INC (MED) filed an 8-K on October 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 FY2026 earnings release issued October 26, 2026.

What are the latest MED SEC filings?

MEDIFAST INC (MED) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 26, 2026, an 8-K current report on October 26, 2026 and a Form 4 insider filing on November 20, 2026.

What is MED's SEC CIK number?

MEDIFAST INC (MED)'s SEC Central Index Key (CIK) is 910329. EDGAR lists every MED filing under that number.

Ask anything about MED

The research agent reads MED's filings, financials, insider trades and 13F holders, then answers with sources.